Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). In the United States and Japan, NSCLC accounts for more deaths each year than do colorectal cancer, breast cancer, and prostate cancer combined.

(Photo: )

Non-Small-Cell Lung Cancer is a new study from Decision Resources, Inc., that examines emerging agents in the development pipeline for this indication and provide an analysis of the NSCLC market over a 1999-2009 study period. NSCLC merits increased interest from pharmaceutical R&D programs because the recent introduction of more-active combinations of chemotherapy agents has changed the previous perception among oncologists and other specialists that NSCLC is a chemoresistant cancer. Furthermore, the large patient population, combined with substantial unmet treatment needs, provides a significant market opportunity for emerging NSCLC therapeutics. We expect the use of chemotherapy to treat NSCLC (at all disease stages) will continue to increase throughout our study period.

In recent years, a host of emerging agents and novel treatment combinations have received attention. Rational-treatment approaches that target the etiology of tumor cells, as well as their abnormal behavior and expression, are currently in Phase II and III development. These approaches include angiogenesis-inhibiting agents, matrix metalloproteinase inhibitors (MMPIs), signal transduction inhibitors, antibodies to surface markers and growth factors, gene therapies, vaccines, and bioreductive agents. Intense research is focusing on novel combinations of agents with high activity, such as the taxanes, gemcitabine, and vinorelbine. These emerging therapies, if they win regulatory approval, will boost the overall size of the NSCLC therapeutic drug market. In 1999, the seven-country market for drugs to treat NSCLC reached nearly $870 million. We expect this market to grow at an annual rate of 8.8% to exceed $2 billion by 2009.

Non-Small-Cell Lung Cancer is part of Onkos, a multiclient service that evaluates the commercial potential of drugs in research and development to treat cancer.

Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or (e-mail). In Europe, contact Ms. Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or (e-mail).

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for nearly 30 years, assessing industry trends in the international health care and pharmaceutical industries. Drawing on a closely linked international network of experts, Decision Resources offers its clients the most comprehensive analyses of therapy markets available.


AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-487-3753,

Decision Resources Study Evaluates the Clinical Progress and Commercial Potential of Emerging Matrix Metalloproteinase Inhibitors

View Now